Pharmaceutical Strategic Alliances 2012

September 17-19, New York City

Hear firsthand from some of the industry’s most sought after minds at PSA2012, the only conference to provide direct access to the invaluable knowledge capital of pharma’s C-level execs and their biotech counterparts. PSA2012 will employ a case study format to illustrate real solutions to real industry challenges. You’ll have the opportunity to ask questions and initiate valuable dialogue with expert presenters and key opinion leaders, who will address your top-of-mind issues for today and tomorrow.

2011 Featured Speakers Included:

Lamberto Andreotti
Chief Executive Officer
Bristol-Myers Squibb

Fred Paster
Vice President, New Products
Millennium

George Scangos
CEO
Biogen-Idec

Adele Gulfo
President and General
Manager, US Primary Care Pfizer

Kristin Peck
Executive Vice President, Worldwide Business Development and Innovation
Pfizer

David Holveck
CEO
Endo Pharmaceuticals

Tom Heyman
Executive Vice President of Business Development and Managing Director
Janssen Pharmaceutica, N.V.

Wael Fayad
Vice President, Business Development
Forest Laboratories Inc.

You also heard strategies and case studies from top industry leaders, including:

Håkan Björklund, PhD, CEO, Nycomed
Ian Tomlinson, SVP, Biopharmaceutical R&D and Worldwide Business Development, GlaxoSmithKline
Jeremy M. Levin, SVP, Strategic Transactions, Bristol-Myers Squibb
Barbara Yanni, Vice President & Chief Licensing Officer, Merck and Company
Jose-Carlos Gutiérrez-Ramos SVP, Research and Development, Biotherapeutics, Pfizer
Christopher Haskell, PhD, Head of Science Hub US, Bayer Healthcare Pharmaceuticals
David M. Reese, M.D., Vice President, Medical Sciences, Amgen Inc.
Dennis Urbaniak, VP US Diabetes Division, Sanofi
Kim Park, Partner, Janssen Healthcare Innovation, Johnson & Johnson
Diem Nguyen, PhD, General Manager, Biosimilars, Pfizer
Michael Kamarck, President of Merck BioVentures; SVP, Vaccines and Biologics MMD, Merck and Company
Mark McCamish, Head of Global Biopharmaceuticals Development, Sandoz
Anna Protopapas, Global Business Development Head, Takeda Pharmaceutical Co
Nic Dracopoli, PhD, VP Biomarkers, Ortho Biotech Oncology R&D, Johnson & Johnson
Jerry McMahon, PhD, Senior Vice President, Research & Development, Head Oncology Innovative Medicines unit, MedImmune

Feedback about PSA

“The moderators had done their homework with the respective panels. The format was much more informative and allowed a healthy debate on the various topics discussed.”
– Sam Rasty, PhD Director, Corporate Development, Endo Pharmaceuticals

“PSA has an unique structure, participants and venue for top Pharma executives, which address the most relevant issues to the industry today. A must-event for pharma executives who want to move forward in the right direction.”
– Robert DeBenedetto, CEO, SFJ Pharmaceuticals, Inc.

“Well organized. Well attended. Moderators kept panel members focused on relevant topics; good balance between high-level and details. Great way to meet key decision makers.”
– Peter Kolchinsky, Managing Partner, RA Capital

“Very good information presented during the the panel sessions. Excellent participants with a clear understanding and influence of future pharma/biotech trends.”
– Joe Panegasser, Director, Alliance Management PPD Inc.

Global Sponsors